J. Craig Venter, Pioneering Genomics Scientist, Dies at 79
Similar Articles
NIH Funding Shifts and Delays Impact Biomedical Research
Botanist Peter Hamilton Raven Dies at 89
New Platform Tracks How Genetic Errors Drive Disease, Reveals Shared Drug Resistance Pathways
Scientists Map Key Step in Enterovirus Replication, Opening Path for New Antiviral Drugs
Mayo Clinic Researchers Develop New Method to Tag Aging 'Zombie' Cells
J. Craig Venter, a scientist who helped sequence the human genome and pioneered synthetic biology, has died at 79. His work led to faster, cheaper methods for decoding DNA and advanced the creation of synthetic life. He was hospitalized following side effects from cancer treatment.
Facts First
- J. Craig Venter has died at 79 after hospitalization for side effects from cancer treatment.
- His company Celera Genomics competed with the government-funded Human Genome Project to sequence the human genetic code.
- He pioneered the 'whole genome shotgun method' as a cheaper, faster sequencing approach.
- He was the first person to sequence and publish his own individual genome.
- His research team created a bacterial cell controlled by lab-synthesized DNA, advancing synthetic biology.
What Happened
J. Craig Venter, a scientist who played a key role in sequencing the human genome, has died at the age of 79, according to the J. Craig Venter Institute. The institute stated that Venter had been hospitalized following unexpected side effects that arose during treatment for a recently diagnosed cancer. His company, Celera Genomics, attempted to sequence the human genetic code before the government-funded Human Genome Project. Venter pioneered the 'whole genome shotgun method' as a cheaper and faster approach to sequencing.
Why this Matters to You
Venter's work directly accelerated the field of genomics, which may affect your healthcare. The faster, cheaper sequencing methods he championed have helped make genetic testing more accessible. His team's creation of a bacterial cell controlled by synthetic DNA advanced synthetic biology, a field that could lead to new medicines and materials.
What's Next
Venter's legacy in genomics and synthetic biology is likely to continue influencing scientific research and medical innovation. The techniques and competitive model he introduced may continue to drive progress in understanding and manipulating genetic code.